Exposure-Matching Dose Adjustment for Organ-Function Changes

Why Matching Exposure Is Not the Same as Matching Concentrations

When organ function changes, drug clearance may change as well. A straightforward starting point is to adjust the amount of drug given, or the time between doses, so that average exposure remains similar. But an exposure-matching calculation does not automatically preserve every feature of the concentration-time profile. In particular, the peak and trough may change even when average steady-state concentration is unchanged.

The calculations here use a deliberately simple model to make the distinction clear. They describe a hypothetical drug with linear, time-invariant pharmacokinetics. In practice, the calculation is a model-based starting point: the relevant exposure target, patient-specific factors, uncertainty in clearance, and clinical monitoring still matter.

Definition: Let \(D\) be the amount given at each dose, \(\tau\) the dosing interval, \(CL\) systemic clearance, and \(F\) the fraction of the dose reaching systemic circulation. AUC is the area under the concentration-time curve. Average steady-state concentration over an interval is the AUC during that interval divided by \(\tau\). When \(F\), dose, and clearance are constant, the AUC during one dosing interval is \(F D/CL\), and average steady-state concentration is \(F D/(CL\tau)\).

Assumptions Behind Clearance-Based Scaling

The simple scaling rules apply when pharmacokinetics are linear over the relevant dose range: doubling the dose doubles exposure, and clearance does not depend on concentration. Clearance is assumed to be stable within each regimen, and the patient is assumed to have reached steady state under that regimen before a steady-state average or trough is interpreted. The fraction \(F\) is assumed unchanged between the original and adjusted regimens. For the peak-and-trough equations below, use a one-compartment model with instantaneous intravenous bolus doses and a constant volume of distribution \(V\).

These are assumptions, not automatic properties of every drug or patient. If bioavailability changes, clearance is concentration-dependent, organ function is changing quickly, or another process substantially contributes to the concentration profile, a clearance-only scaling rule may not preserve the intended exposure. The equations also do not establish that a particular exposure is effective or safe; they describe how modeled exposure changes when the regimen changes.

Deriving the Exposure-Matching Rules

At periodic steady state, the amount of drug in the body at the beginning and end of a dosing interval is the same. Therefore, the amount entering the systemic circulation during an interval, \(F D\), equals the amount eliminated during that interval. Under linear clearance, the elimination rate is \(CL\,C(t)\), so integration over the interval gives the AUC relationship.

F D = \int_0^\tau CL\,C(t)\,dt = CL \int_0^\tau C(t)\,dt = CL\cdot AUC_\tau

Thus \(AUC_\tau=F D/CL\). Dividing by the interval gives average steady-state concentration. If the goal is to preserve this average after clearance changes from \(CL_0\) to \(CL_1\), set the old and new averages equal:

\frac{F D_0}{CL_0\tau_0} = \frac{F D_1}{CL_1\tau_1} \quad\Longrightarrow\quad \frac{D_1}{\tau_1} = \frac{D_0}{\tau_0}\frac{CL_1}{CL_0}

This equation describes the required change in dose rate when \(F\) is unchanged. Two common choices follow. If the interval is held fixed, scale the dose in proportion to clearance. If the dose is held fixed, change the interval inversely with clearance.

\text{Fixed interval:}\quad D_1=D_0\frac{CL_1}{CL_0} \qquad\qquad \text{Fixed dose:}\quad \tau_1=\tau_0\frac{CL_0}{CL_1}

A related distinction is important: \(AUC_\tau\) is the exposure during one interval, whereas average concentration is \(AUC_\tau/\tau\). Increasing the interval while leaving the dose unchanged increases the AUC per interval, even if average concentration over time is preserved.

Worked Example: Reducing the Dose at a Fixed Interval

Suppose a hypothetical patient receives 150 mg intravenously every 12 hours. Before an organ-function change, clearance is estimated as 3.0 L/h. After the change, assume clearance is 1.5 L/h. Assume \(F=1\), linear pharmacokinetics, unchanged \(V\), and stable clearance. Find the dose for the same average steady-state concentration if the interval remains 12 hours.

With the interval fixed, scale the dose by the clearance ratio:

D_1=150\ \mathrm{mg}\times\frac{1.5\ \mathrm{L/h}}{3.0\ \mathrm{L/h}} =75\ \mathrm{mg}

The original average steady-state concentration is \(150\ \mathrm{mg}/[(3.0\ \mathrm{L/h})(12\ \mathrm{h})]=4.167\ \mathrm{mg/L}\). The adjusted average is \(75\ \mathrm{mg}/[(1.5\ \mathrm{L/h})(12\ \mathrm{h})]=4.167\ \mathrm{mg/L}\). The units reduce to mg/L in both calculations.

For perspective on the profile, suppose \(V=30\ \mathrm{L}\). The original elimination rate constant is \(k=CL/V=3.0/30=0.1000\ \mathrm{h}^{-1}\). For repeated instantaneous intravenous doses at steady state, the peak just after a dose and the trough just before the next dose are

C_{\max,ss}=\frac{D/V}{1-e^{-k\tau}}, \qquad C_{\min,ss}=C_{\max,ss}e^{-k\tau}

Originally, \(k\tau=(0.1000\ \mathrm{h}^{-1})(12\ \mathrm{h})=1.20\). Therefore, \(C_{\max,ss}=(150/30)/(1-e^{-1.20})=7.155064\ \mathrm{mg/L}\), and \(C_{\min,ss}=7.155064e^{-1.20}=2.155064\ \mathrm{mg/L}\). Rounded for reporting, these are 7.16 mg/L and 2.155 mg/L.

After dose reduction, \(k=1.5/30=0.05000\ \mathrm{h}^{-1}\), so \(k\tau=0.6000\). The peak is \((75/30)/(1-e^{-0.6000})=5.540922\ \mathrm{mg/L}\), and the trough is \(5.540922e^{-0.6000}=3.040922\ \mathrm{mg/L}\). The average matches, but the peak is lower and the trough is higher than before. All reported peaks and troughs were calculated from the unrounded values.

Changing the Interval Instead

At a fixed dose, a fall in clearance raises average concentration unless the time between doses is lengthened. The inverse-clearance rule provides an interval that preserves average steady-state concentration under the stated assumptions. This option can produce a different peak-and-trough pattern from reducing each dose while retaining the original interval.

Worked Example: Lengthening the Interval at a Fixed Dose

Use the hypothetical values in the preceding example: 150 mg every 12 hours, clearance falling from 3.0 L/h to 1.5 L/h, and \(V=30\ \mathrm{L}\). Keep the dose at 150 mg and calculate an interval that preserves average concentration.

The fixed-dose rule gives

\tau_1=12\ \mathrm{h}\times\frac{3.0\ \mathrm{L/h}}{1.5\ \mathrm{L/h}} =24\ \mathrm{h}

The new average is \(150\ \mathrm{mg}/[(1.5\ \mathrm{L/h})(24\ \mathrm{h})]=4.167\ \mathrm{mg/L}\), the same as the original average. The new elimination rate constant is \(k=1.5/30=0.05000\ \mathrm{h}^{-1}\), and \(k\tau=(0.05000)(24)=1.20\). Because the dose, \(V\), and \(k\tau\) match their original values, the steady-state peak and trough are also the original values: 7.155064 mg/L and 2.155064 mg/L, or 7.16 mg/L and 2.155 mg/L at the stated reporting precision.

In this particular model, lengthening the interval exactly offsets the reduced elimination rate in the peak-and-trough equations. But the AUC per interval is now \(150/1.5=100\ \mathrm{mg\cdot h/L}\), compared with \(150/3.0=50\ \mathrm{mg\cdot h/L}\) originally. It is twice as large because the interval is twice as long. Average concentration is unchanged because this larger interval AUC is divided by a correspondingly longer interval.

Combining Dose and Interval Changes

Dose and interval can be changed together. The target equation specifies their relationship but does not select a unique regimen: many dose-interval combinations give the same average concentration. Practical constraints such as available dosage forms, the consequences of a missed dose, and whether peak or trough limits matter can help determine which combination is worth evaluating. A regimen that matches an average is not necessarily appropriate if the clinical target is specifically a peak or a trough.

Worked Example: Matching Average Concentration With Both Changes

A hypothetical regimen is 200 mg every 12 hours at clearance \(CL_0\). Suppose clearance changes to \(0.60CL_0\), and a feasible new interval is 18 hours. Assume \(F\) is unchanged and pharmacokinetics remain linear. What dose preserves average steady-state concentration?

Use the combined scaling relationship:

D_1=D_0\frac{CL_1}{CL_0}\frac{\tau_1}{\tau_0} =200\ \mathrm{mg}\times0.60\times\frac{18\ \mathrm{h}}{12\ \mathrm{h}} =180\ \mathrm{mg}

The new dose rate is \(180/18=10.00\ \mathrm{mg/h}\); the original is \(200/12=16.67\ \mathrm{mg/h}\). The new clearance is \(0.60CL_0\), so the ratio of new to original average concentration is \((10.00/16.67)/0.60=1.000\), up to rounding. The AUC per interval increases by a factor of \(180/(200\times0.60)=1.50\), matching the interval increase from 12 to 18 hours. This example establishes an average-exposure match only; without further profile information, it does not show that peak and trough concentrations match.

How to Choose and Check an Adjustment

The central question is which exposure feature the clinical target actually concerns. These options are not interchangeable:

Adjustment or target	What the simple rule matches	What it does not guarantee
Change dose; keep interval fixed	Average concentration and AUC per interval, if clearance and \(F\) assumptions hold	The original peak or trough
Keep dose; change interval inversely with clearance	Average concentration over time	The same AUC per interval in calendar time; nor, in general, the same profile across models
Change dose and interval together	Average concentration if the dose-rate relationship is satisfied	A particular peak or trough without evaluating the concentration-time profile
Target a peak or trough	The specified concentration, if calculated using an appropriate model and regimen	Matching the average or the other concentration unless checked separately

For a one-compartment intravenous bolus model, the peak and trough depend on \(D/V\) and \(k\tau\), not only on the dose rate \(D/\tau\). Thus two regimens with the same average can have different fluctuations. When peak or trough is the relevant goal, calculate the profile with a suitable pharmacokinetic model and verify the specific concentration target rather than inferring it from an average-exposure match.

Diagnostics, Limitations, and a Common Pitfall

Before using a clearance ratio, check whether the inputs represent comparable conditions. A clearance estimate based on an inappropriate sampling time or a patient who has not reached steady state may not support the calculation. Confirm the intended dosing interval, dose units, route, and the exposure measure being matched. If observations after an adjustment disagree with the predicted direction or magnitude, revisit the assumptions and inputs rather than applying the same ratio repeatedly.

The simple rules are limited when \(F\) changes, when clearance varies over time, or when pharmacokinetics are nonlinear. Changes in distribution volume can alter peak and trough concentrations even if the average-exposure calculation appears sound. Likewise, a dose-rate match does not account for active metabolites or for a therapeutic target tied to a particular concentration or time course. In these circumstances, a more complete model and relevant clinical measurements may be needed.

Common pitfall: “The average matches, so the peak and trough must match.” This confuses average exposure, which depends on dose rate relative to clearance, with concentrations at particular times, which also depend on the shape of the concentration-time profile.
Correction: Calculate the average and the concentration profile separately when both matter. For the example above, reducing the dose at a fixed interval preserved the 4.167 mg/L average, but changed the peak from 7.155064 to 5.540922 mg/L and the trough from 2.155064 to 3.040922 mg/L.
Another pitfall: treating AUC per interval as average concentration. Average concentration is \(AUC_\tau/\tau\); when the interval changes, the AUC per interval can change even if the average is preserved.

Key takeaway: With unchanged bioavailability and linear, stable clearance, preserve average steady-state concentration by matching dose rate to clearance: \(D_1/\tau_1=(D_0/\tau_0)(CL_1/CL_0)\). Then assess peak, trough, or other clinically relevant profile features separately.

Check Your Understanding

Work through each question, then compare with the solutions.

A hypothetical regimen is 100 mg every 8 hours. Clearance falls to 80% of its original value. With the interval fixed and unchanged bioavailability, what dose preserves average steady-state concentration?
A hypothetical regimen is 240 mg every 12 hours. Clearance doubles. If the dose is held fixed, what interval preserves average steady-state concentration?
Explain why doubling the interval while keeping the dose unchanged can preserve average concentration after clearance halves, even though AUC per interval changes.
Why is matching average steady-state concentration not, by itself, evidence that a target trough concentration has been met?

Solutions. (1) \(100\ \mathrm{mg}\times0.80=80\ \mathrm{mg}\) every 8 hours. (2) \(\tau_1=12\ \mathrm{h}\times CL_0/(2CL_0)=6\ \mathrm{h}\). (3) Halving clearance and doubling the interval leave \(D/(CL\tau)\) unchanged, while \(D/CL\), the AUC per interval, doubles; dividing that doubled AUC by the doubled interval gives the same average. (4) An average summarizes exposure over the interval, whereas a trough is the concentration at a particular time. The concentration-time profile can change while its average remains constant, so the trough must be calculated or measured separately when it is the target.